The following speakers are confirmed for the afternoon open session.
- Professor Mike Philpott
Blizard Institute, QMUL
Mike Philpott is currently Professor of Cutaneous Biology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London. Mike originally studied Marine Biology and Biochemistry at the University of Wales, Bangor graduating in 1986. He obtained his D. Phil from the University of Oxford in 1990 the title of his thesis was ‘Studies on isolated hair follicles’ from which he published on the in vitro culture and growth of human hair follicles now referred to as the ‘Philpott model’. He continued his research into hair follicle biology at the University of Cambridge from 1990 until 1994 and Unilever Research from 1994 to 1996. He was appointed to a lectureship at Barts and The London in 1996. He was promoted to senior lecturer in 1999; Reader in 2003 and Professor of Cutaneous Biology in 2005. He was centre lead for Cutaneous Research from 2006 to 2015. His research interests include hair biology, steroidogenesis and sebocyte differentiation and the role of hedgehog signalling and Gli transcription factors in the development of basal cell carcinoma. A major focus of his research has always been use of human tissue and human models.
- Dr Gerry Kenna
Scientific Director, FRAME (Fund for the Replacement of Animals in Medical Experiments)
Dr. Gerry Kenna is Scientific Director of FRAME (www.frame.org.uk), which is a leading independent charity focused on developing and promoting non-animal scientific research methods. He has specific expertise in the mechanisms by which drugs cause human idiosyncratic adverse reactions, how novel preclinical methods can be used in drug discovery to reduce the likelihood that these will arise, and how these can be detected and managed during clinical trials. This was acquired over many years, while working in industry (at AstraZeneca, Syngenta, and Zeneca) and in academia (at Imperial College School of Medicine London, National Institutes of Health USA, King’s College Hospital Medical School London UK and the National Institute for Medical Research London). He received a BSc in Biochemistry from the University of Leeds UK and a PhD in Biochemistry from the University of London UK and has authored or co-authored >100 scientific publications.
- Kathy Archibald
Director, Safer Medicines Trust
Kathy Archibald is the director of Safer Medicines Trust. She worked in drug development for pharmaceutical and biotechnology companies (Searle, MediSense) after graduating in genetics from Nottingham University. She then worked for several years in environmental education and for a children's charity. In 2005, she founded Safer Medicines Trust, to confront the unspoken problem in pharmaceutical research of the poor relevance of much research (based on animals) to human medicine. Safer Medicines Trust exists to improve the safety of medicines for patients, through an increased focus on human biology throughout the drug development process.
- Dr Roumteen Keshe
Business Development Manager, CN Bio Innovations
Dr Keshe received his Masters of Engineering from University College London (UCL) in 2009 before undertaking a doctorate in collaboration between UCL and MedImmune for the Bioprocessing of cell derived antibody therapeutics. During his time with MedImmune he worked with a number of international teams in the development of devices to improve the robustness and efficacy of MedImmune’s pipeline therapies. He has been involved in a number of Biotech and tech start-ups and received training in the creation and management of ventures using cutting edge technology at the London Business School. At CN Bio Dr Keshe is currently involved in the commercial aspects of bringing the leading Organ-on-a-chip technology to market, with the long term goal of using the models to discover therapies using their more physiologically relevant models.
- Dr Elliot Lilley
Senior Scientific Officer, RSPCA
Dr Elliot Lilley is a Senior Scientific Officer within the RSPCA Research Animals Department, which works to achieve more effective ethical review of animal use and implementation of the Three Rs: http://science.rspca.org.uk/sciencegroup/researchanimals
He received his PhD in Pharmacology from King’s College London in 1997 and then began a 15 year career in the pharmaceutical industry; initially at the James Black Foundation and latterly at Novartis. In 2012, he joined the RSPCA research animals department where his main areas of work relate to promoting refinement, including reducing severe suffering, experimental design, and translational validity. More information on our work towards ending severe suffering can be found here: www.rspca.org.uk/severesuffering
Additional speakers and titles for all the talks will be confirmed in due course. Please check again soon.